Blood Tumour Markers Screening

Non-invasive blood panel screening for multiple cancer-related tumour markers including nasopharyngeal carcinoma, colon, liver, and prostate cancer biomarkers. Includes genetic cancer risk screening option via the LiquidHALLMARK ctDNA test analysing 80 genes.

The Clifford Clinic offers a specialised Blood Tumour Markers Screening programme designed to provide an accessible, non-invasive first line of cancer surveillance. Using a simple blood draw, the panel tests for a range of circulating protein biomarkers that are elevated in the presence of specific cancers — including nasopharyngeal carcinoma (NPC), colorectal cancer, hepatocellular carcinoma (liver cancer), and prostate cancer. For patients seeking a more advanced and genetically precise assessment, the clinic also offers the LiquidHALLMARK genetic cancer risk test. This next-generation liquid biopsy analyses circulating tumour DNA (ctDNA) directly from a blood sample, examining mutations across 80 cancer-related genes and detecting genetic fusions across 10 additional genes. LiquidHALLMARK can identify hereditary cancer predispositions, track minimal residual disease in patients who have previously undergone cancer treatment, and flag early molecular signals before a tumour becomes radiologically visible. Both the standard tumour marker panel and the LiquidHALLMARK test are minimally invasive — requiring only a venepuncture — and can be performed on the same clinic visit, making them efficient additions to a broader health screening appointment or a standalone preventive assessment. Results are reviewed in a consultation with a Clifford Clinic doctor who provides context, advises on normal versus abnormal ranges, and recommends further imaging or specialist evaluation where indicated. Blood tumour marker screening is particularly relevant for individuals aged 40 and above, those with a family history of the cancers covered by the panel, patients who have previously completed cancer treatment and require surveillance, or any individual seeking a comprehensive snapshot of their cancer risk profile. Combined with the clinic's whole-body MRI offering, these blood-based tests form part of a multi-modal early detection strategy that addresses what imaging and blood tests each do best.